Prevalence and molecular detection of extended spectrum beta lactamase producing Burkholderia species from clinical and environmental sources in Abeokuta Ogun State Nigeria.
Barre latérale de l'article
Contenu principal de l'article
Résumé
Background: Extended Spectrum Beta-Lactamase producing bacteria is increasing across the globe. This study investigated the prevalence and molecular detection of ESBL producing Burkholderia sp from clinical and environmental sources in Abeokuta.
Methods: The clinical (135) and environmental (53) samples were examined. Clinical samples were obtained from diabetic (71) and HIV (64) patients. Samples were cultured on Burkholderia cepacia selective agar. Isolates were identified using biochemical procedures and confirmed with 16SrRNA pair of primer set (1500 bp). Antimicrobial susceptility test was performed by disc diffusion method. Production of ESBL were determined using double disc synergy method. Gene encoding CTX-M was probed by PCR and gel electrophoresis using blaCTX-M pair of primer set (650 bp). Fifteen isolates (8%) were identified as Burkholderia sp, using biochemical procedure and confirmed by 16SrRNA gene sequencing.
Results: All the 15 (8%) isolates were resistant to cefuroxime, augumentin (100), ceftazidime (93.3 %), gentamycin (60 %), ofloxacin, cefixime and ciprofloxacin (53.3 %). Least resistance was recorded against nitrofurantoin (26.7 %). Ten (66.7 %) isolates were multidrug resistant. Five (33.3 %) isolates exhibited ESBL production. Three (20 %) harbor CTX-M gene. Highest prevalence of Burkholderia sp was recorded against age group 46-55 (13.3 %). Similarly, higher prevalence of Burkholderia sp was recorded in females 9(6.7 %) than in males 4(3 %). No prevalence was recorded for age group 6-15 and 86-95.
Conclusion: This study revealed that Burkholderia sp were present, isolates obtained were multidrug resistant and harbor blaCTXM in clinical and environmental sources in Abeokuta.
Téléchargements
Renseignements sur l'article
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
Références
Giwa FJ, Ige OT, Haruna DM, Yaqub Y, Lamido T Z, Usman SY. ‘Extended-Spectrum beta lactamase production and antimicrobial susceptibility pattern of uropathogens in a Tertiary Hospital in Northwestern Nigeria’, Journal of Annual Tropical Pathology 2018; (9), 11-6.
Sadeeq R, Tariq A, Ijaz A, Nazir AK, Bo Han, Jian G. The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases. BiolMed Research International Review 2018; 14(6), 951-971.
Ana M, Mirjana S, Matilda S, Ivica S, Jasna P. and Maja P. Occurrence and antibiotic susceptibility profiles of Burkholderia cepaciacomplex in coastal marine environment. International Journal of Environmental Health Research, 2012; 22(6): 531-542.
Ferreira1 CM, William AF, Nayanne CO, Da Silva A, Felipe GN. and Maria GVB. Extended-Spectrum Beta-Lactamase-Producing Bacteria Isolated from Hematologic Patients in Manaus, State of Amazonas, Brazil’, Brazilian Journal of Microbiology 2011; (42), 1076-1084.
Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Update 2016; 28:82–90. https://doi.org/10.1016/j.drup.2016.07.003.
Pedro VB, Mathew PM, Andrew C, Daniel AF, Niamh MM, Marta M, Alexandra RF. Nano strateges to fight multidrug resistance bacteria. A battle of the Titan Fronters i.e. Microbiology 2018; http//doi.org 3389.
O’Neill J. Securing New Drugs for Future Generation:The Pipeline of Antibiotics. London Wellcome trust; 2015; (Google Scholar).
John K. and Gregory D. A Rare Case of Burkholderia cepacia Complex Septic Arthritis. Case report in infectious disease, 2018; https://doi.org/10.1155/2018.6232760.
Eberl L. and Vandamme P. Members of the Genus Burkholderia: good and bad guys. F1000 Research 2016; (5), 1007.
Coulon1 PM. and Déziel, E. Potential of the Burkholderia cepacia complex to produce 4-hydroxy-3methyl-2-alkyquinolines. Front. Cell. Infect. Microbiol. 2019; (9), 33.
Nancy O, Hala Abd El Raouf, Hadir O. & Nermien N. Microbiological assessment of Burkholderia cepacia complex (Bcc) Isolates in Alexandria Main University Hospital. Alexandria Journal of Medicine 2015; (51), 41-46.
Cheesbrough M. District Laboratory Practice in Tropical Countries. 2nd Edn. Cambridge University Press, Cambridge, UK, 2006. ISBN-13: 9781139449298.
Clinical and Laboratory Standards Institute (CLSI) 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017; Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Eleventh Edition.
Frank JA, Reich CI, Sharma S, Weisbaum JS, Wilson BA. and Olsen G J. Critical Evaluation of Two Primers Commonly Used for Amplification of Bacterial 16S rRNA Genes. Applied and Environmental Microbiology 2008; 74(8), 2461-2470.
Yang JL, Wang MS, Cheng AC, Pan KC, Li CF. and Deng SX. A simple and rapid method for extracting bacteria DNA from intestinal microflora for ERIC-PCR detection. World J Gastroenterol 2008; 14(18), 2872-2876.
Sturenburg E, Sobottka I, Feucht HH, Mack D. and Laufs R. Comparison of BD Phoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagnostic Microbiology and infectious Disease, 2003; 45(1),29-34.
Mohammed OH. Clinical study of Burkholderia cepacia Isolated from body infections Plant Archives 2018; (18), 65-72.
El Chakhtoura NG, Saade E, Wilson BM, Perez F, Papp-Wallace KM, Bonomo RA. A 17-Year Nationwide Study of Burkholderia cepacia Complex Bloodstream Infections among Patients in the United States Veterans Health Administration. Clinical Infectious Diseases 2017; 65(8), 1327–1334.
Rastogi N, Khurana S, Veeraraghaven B, Yesurajan Inbanathan F, Rajamani Sekar SK, Gupta D, Goyal k, Bindra A, Sokhal N, Panda A, Malhotra R, Mathur P. Epidemiological investigation and successful management of a Burkholderia cepacia outbreak in a neurotrauma intensive care unit. International Journal of Infectious Disease 2019; (74), 4-11.
Sarah Gl, Eoin M, Elizabeth B, Sally F, Susan L. and Taylor HT. Burkholderia cepacia: An Outbreak in the Peritoneal Dialysis Unit 2019; (39), 1.
Matthaiou DK, E. Chasou, S. Atmatzidis, P. Tsolkas. A Case of Bacteremia due to Burkholderia cepacia in a Patient without Cystic Fibrosis. Respiratory Medicine CME 2011; 4 (14), 145.
Ramsay KA, Butler CA, Paynter S, Ware RS, Kidd TJ, Wainwright CE, Bell SC. Factors Influencing Acquisition of Burkholderia cepacia Complex Organisms in Patients with Cystic Fibrosis. Journal of Clinical Microbiology 2013; 15(12), 3975–3980.
Cecilia, C., Janet, M., Carlos, G., Mel, K., Charlie, C., Timothy, W., Shaff, K., Massina S., Elizabeth, T., Michael, H. and Steven K. Infection with Burkholderia cepacia in Cystic Fibrosis Outcome Following Lung Transplantation American Journal of Respiratory and Critical care Medicine 2001; (163), 43-48.
Dervla TD, Kenna DL, Amy C, Kate M, Claire P, Rachel P, Robert H. and Jane F. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. Journal of Medical Microbiology 2017; (66), 4049-4050.
Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: beyond Pseudomonas and acinetobacter. Indian Journal Medical Microbiology 2011; (29), 4–12.
Singleton A. and Cluck D. The Pharmacist’s Role in Treating Extended-Spectrum Beta- Lactamase Infections. US Pharmacist 2019; 44(4):2-6.
Nonhlanhla M, Sabiha E. and Usha G. NDM-1 novel TEM-205, novel TEM-213 and other Extended-spectrum ?-lactamases Co- Expressed in Isolates from Cystic Fibrosis Patients from South Africa, Southern African Journal of Infection Diseases, 2015; 30(3), 103-107.